XBIT Valuation
XBiotech Inc
$
2.920
- Overview
- Forecast
- Valuation
- Earnings
XBIT Relative Valuation
XBIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XBIT is overvalued; if below, it's undervalued.
Historical Valuation
XBiotech Inc (XBIT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.18 is considered Fairly compared with the five-year average of 32.71. The fair price of XBiotech Inc (XBIT) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：2.92
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
XBiotech Inc. (XBIT) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.28
EV/EBIT
XBiotech Inc. (XBIT) has a current EV/EBIT of -0.28. The 5-year average EV/EBIT is 34.13. The thresholds are as follows: Strongly Undervalued below -82.65, Undervalued between -82.65 and -24.26, Fairly Valued between 92.52 and -24.26, Overvalued between 92.52 and 150.91, and Strongly Overvalued above 150.91. The current Forward EV/EBIT of -0.28 falls within the Historic Trend Line -Fairly Valued range.
0.18
PS
XBiotech Inc. (XBIT) has a current PS of 0.18. The 5-year average PS is 5.22. The thresholds are as follows: Strongly Undervalued below -10.77, Undervalued between -10.77 and -2.77, Fairly Valued between 13.21 and -2.77, Overvalued between 13.21 and 21.20, and Strongly Overvalued above 21.20. The current Forward PS of 0.18 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
XBiotech Inc. (XBIT) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.36
P/FCF
XBiotech Inc. (XBIT) has a current P/FCF of 0.36. The 5-year average P/FCF is -3.27. The thresholds are as follows: Strongly Undervalued below -16.09, Undervalued between -16.09 and -9.68, Fairly Valued between 3.14 and -9.68, Overvalued between 3.14 and 9.55, and Strongly Overvalued above 9.55. The current Forward P/FCF of 0.36 falls within the Historic Trend Line -Fairly Valued range.
XBiotech Inc (XBIT) has a current Price-to-Book (P/B) ratio of 0.51. Compared to its 3-year average P/B ratio of 0.69 , the current P/B ratio is approximately -26.40% higher. Relative to its 5-year average P/B ratio of 0.94, the current P/B ratio is about -45.94% higher. XBiotech Inc (XBIT) has a Forward Free Cash Flow (FCF) yield of approximately -35.77%. Compared to its 3-year average FCF yield of -16.47%, the current FCF yield is approximately 117.18% lower. Relative to its 5-year average FCF yield of -7.60% , the current FCF yield is about 370.61% lower.
0.51
P/B
Median3y
0.69
Median5y
0.94
-35.77
FCF Yield
Median3y
-16.47
Median5y
-7.60
Competitors Valuation Multiple
The average P/S ratio for XBIT's competitors is 34.21, providing a benchmark for relative valuation. XBiotech Inc Corp (XBIT) exhibits a P/S ratio of 0.18, which is -99.47% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of XBIT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of XBIT in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is XBiotech Inc (XBIT) currently overvalued or undervalued?
XBiotech Inc (XBIT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.18 is considered Fairly compared with the five-year average of 32.71. The fair price of XBiotech Inc (XBIT) is between to according to relative valuation methord.
What is XBiotech Inc (XBIT) fair value?
How does XBIT's valuation metrics compare to the industry average?
What is the current P/B ratio for XBiotech Inc (XBIT) as of Aug 09 2025?
What is the current FCF Yield for XBiotech Inc (XBIT) as of Aug 09 2025?
What is the current Forward P/E ratio for XBiotech Inc (XBIT) as of Aug 09 2025?